Rafael Holdings, Inc. cash flow statement
In fiscal 2026, Rafael Holdings, Inc.'s operations generated −$30.0m of cash; it spent $3,000 on capital projects, leaving free cash flow of −$30.0m.
Cash flow statement
| Fiscal year | 2016Jul 2016 | 2017Jul 2017 | 2018Jul 2018 | 2019Jul 2019 | 2020Jul 2020 | 2021Jul 2021 | 2022Jul 2022 | 2023Jul 2023 | 2024Jul 2024 | 2025Jul 2025 | 2026Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | −2 | −2 | −3 | −5 | −16 | −26 | −11 | −8 | −19 | −30 |
| Depreciation and amortisation | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | — | — | 0 | — | 1 | 7 | −1 | 2 | 2 | 2 | 1 |
| Capital spending | 2 | 2 | 1 | 0 | 1 | 0 | 0 | — | 0 | 0 | 0 |
| Free cash flow | −1 | −3 | −3 | −4 | −5 | −16 | −26 | — | −8 | −19 | −30 |
| Free cash flow after stock pay | — | — | −3 | — | −6 | −22 | −25 | — | −10 | −21 | −31 |
| Share buybacks | — | — | — | — | — | — | — | — | 0 | — | — |
| Shares issued | — | — | — | 8 | — | 13 | 99 | 98 | — | 25 | — |
| Quarter | 2025 Q1Oct 2024 | 2025 Q2Jan 2025 | 2025 Q3Apr 2025 | 2025 Q4Jul 2025 | 2026 Q1Oct 2025 | 2026 Q2Jan 2026 | 2026 Q3Apr 2026 | 2026 Q4Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −3 | −2 | −3 | −10 | −7 | −8 | −7 | −8 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Capital spending | 0 | 0 | −0 | −0 | — | — | 0 | −0 |
| Free cash flow | −3 | −2 | −3 | −10 | — | — | −7 | −8 |
| Free cash flow after stock pay | −3 | −3 | −4 | −11 | — | — | −7 | −9 |
Compare with peers
- Medicinova Inc cash flow
- Shattuck Labs, Inc. cash flow
- Longeveron Inc. cash flow
- Dare Bioscience, Inc. cash flow
- Cartesian Therapeutics, Inc. cash flow
Head to head: MNOV vs RFLRFL vs STTKLGVN vs RFL
More: Biotechnology stocks compared, Health Care sector, rankings of US companies